Dr. Richter on Pomalidomide as Sickle Cell Disease Treatment

Video

In Partnership With:

Joshua Richter, MD, hematologist/oncologist, multiple myeloma, John Theurer Cancer Center, discusses using the FDA-approved multiple myeloma drug pomalidomide to treat patients with sickle cell disease.

Joshua Richter, MD, hematologist/oncologist, multiple myeloma, John Theurer Cancer Center, discusses using the FDA-approved multiple myeloma drug pomalidomide to treat patients with sickle cell disease.

Richter says sickle cell disease is difficult to manage as there are few therapies available. Hydroxyurea, which increases the levels of fetal hemoglobin to help prevent sickling, is commonly used to treat sickle cell disease. However, Richter says this therapy can lower blood counts and cause other issues.

Pomalidomide, which was approved by the FDA in February 2013 as treatment for relapsed and refractory multiple myeloma, increases the levels of fetal hemoglobin without some of the toxicities associated with hydroxyurea, Richter says. There is currently a phase I study examining the efficacy of pomalidomide in patients with sickle cell disease.

Though further studies are needed, Richter says researchers may be on to a new way of treating patients with sickle cell disease.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD